Dostarlimab/Chemo/Niraparib Generates PFS Benefit in Primary/Recurrent Endometrial Cancer
Rucaparib Maintenance Elicits Continued PFS Benefit Across Newly Diagnosed Ovarian Cancer Subgroups
Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer
Frontline Durvalumab/Chemo, Then Maintenance Durvalumab ± Olaparib, Improves ORR in Endometrial Cancer
2 Commerce Drive
Cranbury, NJ 08512